AAT patients get a new way to take their meds

As reported in Israel21c:

Approximately one out of every 2,500 people in the world suffers from a deficiency of the Alpha-1 Antitrypsin or AAT protein. Untreated, this genetic disorder – which affects the liver and lungs – is always fatal. Now an Israeli bio-pharmaceutical company has developed a more efficient treatment delivery system, holding out the promise of both an improvement in a patient’s quality of treatment, and their quality of life.

Kamada is no newcomer to drug development and manufacturing. Founded in 1990, the company went public in 2005 and has more than 15 products on the market. But it is hoping that the next generation of its flagship product – an inhalable version of its AAT replacement treatment – will be its biggest winner yet.

Read more here

%d bloggers like this: